AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Neuropathic Pain in Survivors of Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-09-26

Last Posted Date: 2015-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 239

Registration Number: NCT00535067

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: BAY 43-9006
Drug: Paclitaxel
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2007-09-21

Last Posted Date: 2016-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00533585

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Weight Gain Prevention for Breast Cancer Survivors

Not Applicable

Conditions: Breast Cancer

Interventions: Behavioral: Weight Gain Prevention Program
Behavioral: Questionnaire

First Posted Date: 2007-09-21

Last Posted Date: 2020-01-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00533338

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma

Phase 1

Terminated

Conditions: Neuroblastoma

Interventions: Drug: ZD6474
Drug: Retinoic Acid

First Posted Date: 2007-09-21

Last Posted Date: 2011-12-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00533169

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy

Terminated

Conditions: Malignant Neoplasm

Interventions: Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2007-09-19

Last Posted Date: 2020-01-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT00532064

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Valproic Acid and Bevacizumab in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Valproic Acid
Drug: Bevacizumab

First Posted Date: 2007-09-18

Last Posted Date: 2015-01-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 71

Registration Number: NCT00530907

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients With Thoracic Malignancies

Phase 2

Completed

Conditions: Esophageal Cancer
Lung Cancer

Interventions: Procedure: 4D CT scans
Procedure: Lung Function Imaging

First Posted Date: 2007-09-18

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00531180

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Spectroscopy Versus Standard Care in Cervical Cancer Patients

Phase 3

Terminated

Conditions: Cervical Cancer

Interventions: Procedure: Colposcopy
Procedure: Fluorescence Spectroscopy
Procedure: LEEP Procedure

First Posted Date: 2007-09-14

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00529464

Locations: 🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦
British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Azacitidine
Drug: Valproic Acid
Drug: Carboplatin

First Posted Date: 2007-09-14

Last Posted Date: 2013-02-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT00529022

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Effect on Clip Markers After Vacuum-Assisted Biopsy by Postprocedure Mammogram

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Procedure: Breast Biopsy
Procedure: Post Procedure Mammogram

First Posted Date: 2007-09-14

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT00529737

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy